Sensorion SA (ALSEN.PA) climbed +9.81% intraday to €0.46 on 11 Mar 2026 ahead of an earnings update due 12 Mar 2026. ALSEN.PA stock is trading on EURONEXT with volume 1,111,919, well above its average. Investors are watching clinical and cash updates closely. This earnings spotlight explains the near-term drivers and what numbers could move the share price.
ALSEN.PA stock: earnings timing and what to expect
Sensorion reports on 12 Mar 2026. The company is clinical-stage in inner ear therapeutics. Earnings may include cash runway, R&D milestones and program updates for OTOF-GT and SENS-401. Market participants often react to clarity on trial sequencing and financing. Expect commentary on timelines and any near-term partnerships.
Market reaction and intraday price action
ALSEN.PA stock opened at €0.48, hit a day high of €0.49, and closed near €0.46 intraday. The stock gained +9.81% versus yesterday. That move came with volume 1,111,919, nearly 3.13x relative volume. The jump suggests short-term buying ahead of the earnings release, and technical indicators show overbought conditions.
Financial snapshot and valuation metrics
Sensorion carries market cap €141,458,653 with shares outstanding 300,336,842. Latest EPS is -0.09, and PE reads -5.23. Price-to-book stands at 2.48, and price-to-sales is 24.20. Balance-sheet strength is visible: cash per share €0.19 and current ratio 4.90. R&D spend is high, with research-to-revenue at 4.45x, reflecting a development-stage profile.
Meyka AI rates ALSEN.PA with a score out of 100 and technical view
Meyka AI rates ALSEN.PA with a score out of 100: 66.46 / 100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show RSI 70.88 and ADX 36.11, indicating a strong trend but short-term overbought readings.
Price targets, Meyka AI forecast and implied returns
There is no published consensus price target. We offer scenario targets to frame expectations. Bear target €0.15 implies downside -67.29% versus current €0.46. Base target €0.45 implies near-term flat performance. Bull target €0.80 implies upside +74.12%. Meyka AI’s forecast model projects €0.14 for a yearly horizon, implying -68.54% versus current price. Forecasts are model-based projections and not guarantees.
Catalysts, risks and near-term outlook
Near-term catalysts include any clinical timeline updates, partnership news, or cash runway guidance at the earnings call. Key risks are cash burn, trial setbacks, and high valuation metrics relative to revenue. Sector context matters: healthcare equities in Europe trade with an average PB of 2.64. Sensorion’s low debt and solid current ratio provide some cushion, but clinical binary outcomes will drive volatility.
Final Thoughts
ALSEN.PA stock is trading higher intraday on 11 Mar 2026 ahead of a critical earnings update on 12 Mar 2026. The jump to €0.46 on volume 1,111,919 indicates positioning ahead of corporate disclosures. Fundamentals show a development-stage biotech with negative EPS -0.09, high R&D intensity, and a strong current ratio 4.90. Meyka AI rates Sensorion 66.46 / 100 (Grade B, HOLD), reflecting mixed fundamentals and sector dynamics. For scenario planning, our price framework spans a bear target €0.15, base €0.45, and bull €0.80. Meyka AI’s forecast model projects €0.14 yearly, implying -68.54% from the current price. Investors should treat model outputs as projections only. In short, earnings-day headlines and any cash guidance will be the decisive drivers for ALSEN.PA stock. Watch management commentary for financing needs and program timelines before adjusting positions.
FAQs
When does Sensorion report earnings and why does it matter for ALSEN.PA stock?
Sensorion reports on 12 Mar 2026. The update matters because it may include cash runway, R&D milestones and trial timelines. These items often trigger sharp moves in ALSEN.PA stock for clinical-stage companies.
What is Meyka AI’s grade for ALSEN.PA and what does it mean?
Meyka AI scores ALSEN.PA 66.46 / 100 (Grade B, HOLD). The grade blends benchmark, sector, growth, key metrics and analyst signals. It is informational only and not financial advice.
What price targets should investors consider for ALSEN.PA stock?
Scenario targets: Bear €0.15, Base €0.45, Bull €0.80. Meyka AI’s yearly forecast is €0.14, a model projection and not a guarantee. Use targets for risk planning, not trade timing.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)